bioMérieux will be awarded up to EUR54.5 million by France's Agence de l'Innovation Industrielle for molecular biology research
The ADNA program aims to develop personalized medical solutions for cancer, infectious diseases and rare genetic diseases. Four strategically aligned partners, bioMérieux, Généthon, GenoSafe® and Transgene, have teamed up to meet the challenge. An initial partnership between bioMérieux and Ipsen in oncology research has given the project an additional boost.
Over the next ten years, the assistance provided by the agency will help finance programs designed to:
* Find, identify and validate biomarkers. The identification of biomarkers shall help scientists to develop diagnostic tests for earlier disease detection, determine appropriate treatments and monitor treatment response in patients.
* Develop new molecular diagnostic platforms to perform high-value-added analyses of infectious diseases and certain types of cancer.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.